EIKN
Eikon Therapeutics, Inc.
$8.96
-8.38%
$485.1M
No data for this timeframe.
Vol
Market Cap$485.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (83%)
Insider Activity5B / 0S
Insider Net $$33.9M
SEC Reports1
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001861123·Prev Close $9.78
Recent Activity
Jun 1, 2026
SEC
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing
8-K — Impact 5/10
May 30, 2026
Press
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing
Impact 5/10
May 30, 2026
fda
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
<p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eik
Mar 2, 2026
Insider
Klobuchar Michael A sold 87,157 shares
Chief Operating Officer @ $0.00 ($0.00)
Mar 2, 2026
Insider
Thorner Benjamin Bruno sold 67,044 shares
See Remarks @ $0.00 ($0.00)
Mar 2, 2026
Insider
Baynes Roy D. sold 134,088 shares
Chief Medical Officer @ $0.00 ($0.00)
Price Targets
$24.80
+176.8% upside
Strong Buy
Current $8.96
Low $5.00
Median $29.00
High $32.00
5 analysts
$5.00
$32.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Wedbush | MAINTAIN | Underperform → Underperform |
| Mar 31, 2026 | Wedbush | REITERATE | Underperform → Underperform |
| Mar 2, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 2, 2026 | JP Morgan | INITIATE | Overweight |
| Mar 2, 2026 | B of A Securities | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.46 | $-1.64 — $-1.13 | 4 | |
| Next Q | $-1.56 | $-1.77 — $-1.18 | 4 | |
| Next FY | $-6.19 ▼ -9.2% | $-7.86 — $-4.86 | 3% YoY | 5 |
| Current FY | $-6.35 ▼ -9.4% | $-6.82 — $-5.35 | 94% YoY | 5 |
Latest Reports
NEUTRAL
8-K
5/10
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing
Jun 1, 2026
NEUTRAL
Press
5/10
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing
May 30, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 2, 2026 | Klobuchar Michael | A | $0.00 |
| Mar 2, 2026 | Thorner Benjamin | A | $0.00 |
| Mar 2, 2026 | Baynes Roy | A | $0.00 |
| Mar 2, 2026 | FRAZIER KENNETH | A | $0.00 |
| Mar 2, 2026 | Huffines Robert | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
11 unique insiders with 5 transactions. Net insider value: $33.9M ($33.9M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Klobuchar Michael A | Chief Operating Officer | A | 87,157 | $0.00 | $0.00 |
| Mar 2, 2026 | Thorner Benjamin Bruno | See Remarks | A | 67,044 | $0.00 | $0.00 |
| Mar 2, 2026 | Baynes Roy D. | Chief Medical Officer | A | 134,088 | $0.00 | $0.00 |
| Mar 2, 2026 | FRAZIER KENNETH C | Director | A | 25,873 | $0.00 | $0.00 |
| Mar 2, 2026 | Huffines Robert Luther | Director | A | 25,873 | $0.00 | $0.00 |
| Mar 2, 2026 | PERLMUTTER ROGER M | See remarks | A | 268,176 | $0.00 | $0.00 |
| Mar 2, 2026 | Bowie Alfred Lloyd Jr. | Chief Financial Officer | A | 67,044 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 10,266,152 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 1,450,614 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 303,360 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 5,289,322 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 796,380 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 7,807,026 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 10,000,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Lux Venture Partners V, LLC | Director | C | 2,387,705 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 10,266,152 | $0.00 | $0.00 |
| Feb 6, 2026 | PERLMUTTER ROGER M | See remarks | C | 284,857 | $0.00 | $0.00 |
| Feb 6, 2026 | PERLMUTTER ROGER M | See remarks | C | 1,268,891 | $0.00 | $0.00 |
| Feb 6, 2026 | PERLMUTTER ROGER M | See remarks | C | 855,512 | $0.00 | $0.00 |
| Feb 6, 2026 | Column Group IV GP, LP | 10%+ Owner | C | 1,296,629 | $0.00 | $0.00 |
| Feb 6, 2026 | Column Group IV GP, LP | 10%+ Owner | BUY | 1,437,323 | $18.00 | $25.9M |
| Feb 6, 2026 | Column Group IV GP, LP | 10%+ Owner | C | 9,670,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Column Group IV GP, LP | 10%+ Owner | C | 10,467,526 | $0.00 | $0.00 |
| Feb 6, 2026 | Column Group IV GP, LP | 10%+ Owner | C | 827,278 | $0.00 | $0.00 |
| Feb 6, 2026 | Column Group IV GP, LP | 10%+ Owner | C | 5,133,076 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 2,387,705 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 10,000,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 7,807,026 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 796,380 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 5,289,322 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 303,360 | $0.00 | $0.00 |
| Feb 6, 2026 | Wolfe Josh | Director | C | 1,450,614 | $0.00 | $0.00 |
| Feb 4, 2026 | FRAZIER KENNETH C | Director | BUY | 111,111 | $18.00 | $2.0M |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 1,340,878 | $0.00 | $0.00 |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | BUY | 55,555 | $18.00 | $1000.0K |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 10,000,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 2,502,252 | $0.00 | $0.00 |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 282,317 | $0.00 | $0.00 |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 12,123 | $0.00 | $0.00 |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 501,219 | $0.00 | $0.00 |
| Feb 4, 2026 | Foresite Capital Management IV, LLC | 10%+ Owner | C | 1,711,025 | $0.00 | $0.00 |
| Feb 4, 2026 | Wolfe Josh | Director | BUY | 138,888 | $18.00 | $2.5M |
| Feb 4, 2026 | Lux Venture Partners V, LLC | Director | BUY | 138,888 | $18.00 | $2.5M |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 1 strong sell.
Analyst Price Targets
$24.80 mean target
+176.8% upside
Strong Buy (2.00)
$5.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $8.96 |
| Target Low | $5.00 |
| Target Mean | $24.80 |
| Target Median | $29.00 |
| Target High | $32.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.46 | $-1.64 | $-1.13 | — | — | 1↑ 0↓ | $0.0B | — | 4 |
| Next Q 2026-09-30 |
$-1.56 | $-1.77 | $-1.18 | — | — | 1↑ 0↓ | $0.0B | — | 4 |
| Next FY 2027-12-31 |
$-6.19 | $-7.86 | $-4.86 | 2.6% | -9.2% | 1↑ 1↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-6.35 | $-6.82 | $-5.35 | 94.5% | -9.4% | 1↑ 1↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.461 | |
| 7d ago | $-1.283 | -0.179 |
| 30d ago | $0.000 | -1.461 |
| 60d ago | $0.000 | -1.461 |
| 90d ago | $-1.275 | -0.186 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 6 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Wedbush | MAINTAIN | Underperform | Underperform |
| Mar 31, 2026 | Wedbush | REITERATE | Underperform | Underperform |
| Mar 2, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 2, 2026 | JP Morgan | INITIATE | — | Overweight |
| Mar 2, 2026 | B of A Securities | INITIATE | — | Buy |
| Mar 2, 2026 | Mizuho | INITIATE | — | Outperform |
| Mar 2, 2026 | Morgan Stanley | INITIATE | — | Overweight |
| Feb 26, 2026 | Wedbush | INITIATE | — | Underperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 1 | 83% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 1 | 83% | |
| Apr 1, 2026 | 3 | 7 | 1 | 0 | 1 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 30, 2026
fda
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
<p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical compa
May 21, 2026
routine
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
The six accepted presentations highlight clinical progress across Eikon’s pipeline.
Mar 30, 2026
earnings
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Mar 25, 2026
short_interest
FTD: EIKN — 86,545 shares ($1.0M) failed to deliver
Settlement: 20260325, Price: $11.06, FTD Value: $957,187.7, EIKON THERAPEUTICS INC COM
Mar 24, 2026
short_interest
FTD: EIKN — 84,823 shares ($1.0M) failed to deliver
Settlement: 20260324, Price: $11.71, FTD Value: $993,277.33, EIKON THERAPEUTICS INC COM
Mar 23, 2026
short_interest
FTD: EIKN — 56,099 shares ($0.7M) failed to deliver
Settlement: 20260323, Price: $11.82, FTD Value: $663,090.18, EIKON THERAPEUTICS INC COM
Feb 6, 2026
short_interest
FTD: EIKN — 38,773 shares ($0.6M) failed to deliver
Settlement: 20260206, Price: $15.00, FTD Value: $581,595, EIKON THERAPEUTICS INC COM